Pulmonary Arterial Hypertension Market Report 2025

This Pulmonary Arterial Hypertension report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The pulmonary arterial hypertension market size has grown strongly in recent years. It will grow from $8.47 billion in 2024 to $9.24 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increased awareness and diagnosis of pulmonary arterial hypertension (PAH), increased healthcare expenditure, growth in aging population, expansion of pulmonary arterial hypertension treatment options, rise in research and development activities in pulmonary hypertension.

The pulmonary arterial hypertension market size is expected to see strong growth in the next few years. It will grow to $12.97 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to adoption of novel therapies for pulmonary arterial hypertension, increased focus on early detection and diagnosis, growing pipeline of PAH drugs and therapies, integration of precision medicine in PAH treatment, expansion of healthcare infrastructure in emerging markets. Major trends in the forecast period include advancements in medical imaging and diagnostic technologies, collaboration and partnerships for drug development, patient-centric approaches in pulmonary arterial hypertension management, increased use of combination therapy.

The growth of the pulmonary arterial hypertension market is being propelled by the increasing prevalence of pulmonary arterial hypertension (PAH) disease. The rise in PAH cases and the subsequent hospitalization of patients for treatment are expected to drive the demand for relevant drugs in the forecast period. According to the National Organization for Rare Disorders, Inc., a study suggests that new cases of PAH are estimated to occur in one to two individuals per million annually in the USA, equating to 500-1000 new cases each year, with similar incidence rates expected in Europe.

The increasing number of clinical trials for drug development is expected to drive the growth of the pulmonary arterial hypertension market in the future. Clinical trials for drug development are research studies aimed at assessing the safety, efficacy, and potential side effects of new drugs or treatments in humans. These trials specifically for pulmonary arterial hypertension can result in the creation of new and more effective treatments, improving quality of life, enhancing safety and efficacy, facilitating early access, and identifying cost-effective options. For example, in May 2023, Xtalks, a Canada-based company specializing in life science webinars and virtual events, reported that as of May 17, 2023, there were 452,604 clinical studies registered on ClinicalTrials.gov. Out of this total, 64,838 studies were actively seeking participants, marking an increase of 365,000 registered trials since 2021. Therefore, the rise in clinical trials for drug development is fueling the growth of the pulmonary arterial hypertension market.

Major companies in the pulmonary arterial hypertension market are developing advanced products like Winrevair to enhance treatment options and outcomes for patients with this serious condition. For example, in March 2024, Merck & Co. Inc., a US-based multinational pharmaceutical company, launched Winrevair for treating adults with pulmonary arterial hypertension. Winrevair is the first therapy approved by the Food and Drug Administration (FDA) that specifically targets activin signaling for pulmonary arterial hypertension (PAH). This innovative treatment functions by restoring the balance between pro- and anti-proliferative signals, which helps regulate the vascular cell proliferation associated with PAH. Consequently, it introduces a new class of therapy for this condition.

Major companies in the pulmonary arterial hypertension market are developing advanced products like OPSYNVI to offer improved treatment options that enhance patient outcomes and quality of life for individuals suffering from this serious condition. For example, in March 2024, Johnson & Johnson, a US-based multinational company focused on pharmaceuticals, biotechnology, and medical technologies, launched OPSYNVI for the chronic treatment of adults with pulmonary arterial hypertension. OPSYNVI can be used for patients with pulmonary arterial hypertension (PAH) who are either new to treatment or are already taking an endothelin receptor antagonist (ERA) or PDE5 inhibitor, or both. It is also appropriate for those on stable doses of macitentan 10 mg and tadalafil 40 mg, administered as separate tablets.

In May 2024, Gossamer Bio, a US-based biopharmaceutical company specializing in treatments for Pulmonary Arterial Hypertension (PAH), formed a partnership with Chiesi Farmaceutici S.p.A. This collaboration aims to leverage the strengths of both companies to enhance the treatment of pulmonary arterial hypertension (PAH) and accelerate the development of products for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Chiesi Farmaceutici S.p.A. is an Italy-based pharmaceutical company.

Major companies operating in the pulmonary arterial hypertension market include United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.

North America was the largest region in the pulmonary arterial hypertension market in 2024. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Pulmonary arterial hypertension refers to a condition characterized by elevated blood pressure in the arteries of the lungs, leading to damage to the right side of the heart and the lung arteries. This long-lasting and incurable condition results in the constriction and rigidity of the walls of the pulmonary arteries. Pulmonary arterial hypertension drugs are designed to address this condition by relaxing the muscles in the blood vessel walls, increasing blood flow through the lungs, or reversing the effects of substances in the blood vessel walls that cause them to narrow.

The main types of drug classes for pulmonary arterial hypertension include endothelin receptor antagonists (ERAs), PDE-5 inhibitors, prostacyclin and prostacyclin analogs, and soluble guanylate cyclase (SGC) stimulators. Endothelin receptor antagonists (ERAs) are a targeted medication used for treating pulmonary hypertension in patients. Targeted medications aim to reduce the progression of pulmonary hypertension and potentially reverse some of the damage to the heart and lungs. These drugs can be administered through oral, intravenous/subcutaneous, and inhalational modes, and they are distributed through retail and online channels.

The pulmonary arterial hypertension market research report is one of a series of new reports that provides pulmonary arterial hypertension market statistics, including pulmonary arterial hypertension industry global market size, regional shares, competitors with a pulmonary arterial hypertension market share, detailed pulmonary arterial hypertension market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary arterial hypertension industry. This pulmonary arterial hypertension market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pulmonary arterial hypertension market includes revenues earned by entities by idiopathic, heritable, and drug and toxin-induced. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.